At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Dalfampridine +1 moredrug
Likely dose
Dalfampridine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapeutic Effect of Dalfampridine on Gait Incoordination in Spinocerebellar Ataxias- A Randomized, Double-blinded, Placebo-controlled, Crossover Clinical Trial
In Brief
A clinical study evaluating Dalfampridine and Placebo for Spinocerebellar Ataxias Type 1 and 3 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Investigators expect there will be improvement in walking speed and steadiness after taking Dalfampridine, thereby improving activities of daily living and enhancing social and occupational functions for patients with spinocerebellar ataxia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
CountriesUnited States
CollaboratorsAcorda Therapeutics
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMar 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 14, 2013
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.3 years ago
Interventions
Dalfampridinedrug
Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
Placebodrug
Placebo will be administered orally every 12 hours, for a 4 week period.